Investing.com - Financial Markets Worldwide

Halozyme’s CEO Helen Torley sells $3.8m in shares

Published 14/08/2025, 00:28
Halozyme’s CEO Helen Torley sells $3.8m in shares
HALO
0.97%

Helen Torley, President and CEO of Halozyme Therapeutics, INC. (NASDAQ:HALO), a $7.6 billion biotechnology company with an "EXCELLENT" financial health rating according to InvestingPro, sold a total of 59,850 shares of common stock between August 11 and August 13, 2025, for approximately $3.8 million. The sales prices ranged from $63.008 to $64.828 per share, amid the stock’s strong 36% year-to-date performance.

The transactions, which were executed under a pre-arranged trading plan, also involved the exercise of options to purchase 60,000 shares of Halozyme stock at a price of $8.11 per share, for a total value of $486,600.

Following these transactions, Torley directly owns 733,719 shares of Halozyme Therapeutics , INC.

In other recent news, Halozyme Therapeutics reported its second-quarter 2025 earnings, revealing a significant earnings per share (EPS) beat but a revenue miss. The company achieved an EPS of $1.54, surpassing the forecasted $1.24 by 24.19%, while revenue fell short at $206 million compared to the expected $286.01 million, marking a 27.97% drop. Following these results, Citizens JMP raised its price target for Halozyme to $91 from $78, maintaining a Market Outperform rating. The firm highlighted that Halozyme’s financial results exceeded both its own and consensus estimates, prompting an increase in top-line and bottom-line guidance for 2025. Additionally, Morgan Stanley upgraded the stock to Overweight, raising the price target to $75 from $62, citing the positive implications of the ORPHAN Cures Act. Goldman Sachs also adjusted its price target to $56 from $55, maintaining a Neutral rating, after analyzing the potential impacts of the Inflation Reduction Act on Part B drugs. These developments reflect the ongoing adjustments and evaluations by analysts in response to Halozyme’s recent financial performance and legislative changes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.